title: Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: Results of a phase III, open-label, 6-month extension study.
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Saroj
authors.initials: S
authors.lastname: Vadhan-Raj
authors.affiliation: Toronto Digestive Disease Associates, Inc, Vaughan, Ontario, Canada.
authors.forename: David C
authors.initials: DC
authors.lastname: Ford
authors.affiliation: AMAG Pharmaceuticals, Inc, Waltham, Massachusetts.
authors.forename: Naomi V
authors.initials: NV
authors.lastname: Dahl
authors.affiliation: AMAG Pharmaceuticals, Inc, Waltham, Massachusetts.
authors.forename: Kristine
authors.initials: K
authors.lastname: Bernard
authors.affiliation: AMAG Pharmaceuticals, Inc, Waltham, Massachusetts.
authors.forename: Zhu
authors.initials: Z
authors.lastname: Li
authors.affiliation: AMAG Pharmaceuticals, Inc, Waltham, Massachusetts.
authors.forename: Lee F
authors.initials: LF
authors.lastname: Allen
authors.affiliation: AMAG Pharmaceuticals, Inc, Waltham, Massachusetts.
authors.forename: William E
authors.initials: WE
authors.lastname: Strauss
mesh_terms: D000284:Administration, Oral; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D052203:Ferrosoferric Oxide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D016896:Treatment Outcome
chemical_list: D006397:Hematinics; D052203:Ferrosoferric Oxide